- Mechanisms of resistance and expanded therapies
- Progress with response prediction and TKI discontinuation
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Mechanisms of resistance and expanded therapies
Michael W. Deininger, Jane F Apperley, Christopher Kevin Arthur, et al.
Xiaoshuai Zhang, Zongru Li, Yazhen Qin, et al.
The use of the 3rd generation TKI therapy achieves a poor response to ASXL1 mutations with a VAF ≥ 17% and PHF6 mutations. There were also worse results with STAT5A and RUNX1 mutations as well as high-risk ACAs.
Jorge E. Cortes, Tapan Saikia, Dong-Wook Kim, et al.
Vodobatinib in patients with heavily previously treated CML who failed ≥ 3 previous TKIs, including ponatinib, remains beneficial with a long-term safety and efficacy.
Michael J. Mauro, Yosuke Minami, Delphine Rea, et al.
After a median follow-up time of 19.2 months, the study authors assume a positive benefit-risk profile of asciminib compared to BOS and recommend the use of asciminib as a new therapy in this heavily pretreated patient population.
Jiang Qian, Dayu Shi, Zongru Li, et al.
According to the study authors, olverembatinib is efficacious and well tolerated in TKI-resistant CML-CP or CML-AP and long-term treatment.
Mhairi Copland, Daniel Slade,Graham McIlroy, et al.
Ponatinib can be safely combined with high-dose chemotherapy to bring about a return to the chronic phase in patients with BP-CML, making ponatinib an effective new treatment strategy for these high-risk patients. Patients who respond to therapy and who then undergo alloSCT can benefit from long-term disease-free survival.
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Progress with response prediction and TKI discontinuation
Koji Sasaki, Elias J. Jabbour, Ghayas C. Issa, et al.
Just as effective as standard-dose dasatinib is low-dose dasatinib, which has fewer intolerances. This results in a favorable outcome.
Xiaoshuai Zhang, Xiaojun Huang, Robert Peter Gale and Qian Jiang.
The predictive score for FFS described by the study authors identifies people with newly diagnosed chronic CML with initially imatinib with different probabilities of success. This should enable doctors to select the best TKI therapy strategy in this setting.
Francois-Xavier Mahon, Johan Richter, Andreas Hochhau, et al.
This final analysis of the largest TFR study confirms the MRecFS and MRecTFS rates from the interim analysis. However, late molecular relapse (15% between 6 and 36 months) was observed. Nevertheless, almost half (46%) were still in MRecTFS at 3 years.
Katia B Pagnano, Chung Hoow Kok, Michael J. Mauro, et al.
Older CML patients (> 75 years) with COVID-19 have a higher mortality rate. Likewise for CML / COVID-19 patients with cardiovascular or pulmonary comorbidities and from countries with low and middle income. There were also more deaths in patients in advanced stages and in those without MMR.
Delphine Rea, Slawomira Kyrcz-Krzemien, Paolo Sportoletti, et al.
An additional year of NIL-CONS for CML-CP who achieved a sustained DMR after switching from IM after 2 years with NIL does not bring any significant incremental advantage in terms of TFR success. The efficacy of NIL (300 mg BID) in achieving MR in patients who were unable to achieve sustained DMR with 1st-line IM for ≥ 24 months was confirmed without any new safety signals.
Sen Yang, Xiaoshuai Zhang, Xiaojun Huang, et al.
See abstract for more info.